source
- GSK CEO warns possible team reorganization if upcoming Phase 3 readouts fall shortGSK's chief executive Luke Miels told analysts during the first‑quarter earnings call that the company has several pivotal Phase 3 trials slated for this year. He said that if those late‑stage rea…
- AbbVie's Skyrizi sales growth raises investor worries about J&J competitionDuring AbbVie's first-quarter earnings call, analysts focused on the company's immunology franchise and asked how it would defend Skyrizi against emerging competition from Johnson & Johnson. The c…